Phase 2 N=84 Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Progression Free Survival (PFS) at 9 Month — 25.1; 35 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 OSU Plate Waste Study
Plate Waste
Primary: Percent of Food Items Across All Participants That Were Not Fully Eaten Over Approximately 1 Week and That Were Not Kept as a Leftover for Subsequent Consumption…
N/A N=10 STAMP+CBT mHealth for Cancer Pain
Active Cancer · Active Cancer Treatment · Advanced Cancer
Primary: Overall Intervention Adherence Rate — 15.75 EMA App Surveys
N/A N=273 SHARE: Sharing Healthcare Wishes in Primary Care
Cognitive Impairment
Primary: Average Scores for Patient and Caregiver-Reported Quality of Communication at 6-Months — 3.41; 3.09; 3.06; 1.93 score on a scale
Phase 1 N=11 Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Hepatitis C, Chronic
Primary: Maximum Concentration of Velpatasvir in Maternal Plasma — 381.93 ng/mL
N/A N=68 Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
PMS · Menstrual Pain
Primary: Relief From Premenstrual Cramps [Time Frame: Baseline to 3 Months] — 4.41; 3.48; 3.12; 2.72 score on a scale — p=<0.001
N/A N=193 Improving Diabetic Patient Health Through Assistive-Reading Technology
Diabetes Mellitus, Type 2 · Health Knowledge, Attitudes, Practice · Literacy
Primary: Health Literacy Questionnaire Subscale 9: Understanding Health Information Well Enough to Know What to do — 4.2079; 4.31739 units on a scale — p=.049
Phase 3 N=144 A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
Dravet Syndrome (DS)
Primary: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period — -8.64; -22.16 percent change — p==0.061
N/A N=6 The Perceptual Experience of Argus II Users
Retinitis Pigmentosa
Primary: Number of Phosphenes Perceived — 1.09; 1.43; 1.46; 1.41 number of phosphenes — p=0.002
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
N/A N=168 BOOST: Breastfeeding Onset and Onward With Support Tools
Breastfeeding Duration
Primary: Number of Participants Breastfeeding Their Infants at 1 Month — 76; 74 Participants
N/A N=72 Prevention of Alcohol-related Sexual Revictimization in College
Sexual Assault
Primary: Days Per Month Hazardous Drinking — 7.54; 10.40; 1.97; 1.53 Days per Month Hazardous Drinking — p=<0.99
N/A N=231 ECAP-controlled, Closed-loop Stimulation to Treat Chronic Trunk and/or Limb Pain (ECAP)
Chronic Pain · Back Pain · Pain
Primary: Evoked Compound Action Potentials (ECAPs) as Measured by the Evoke SCS System — 1.3 ratio
Phase 3 N=7,122 Health Information Technology for COVID-19 Testing in Schools (SCALE-UP Counts)
COVID-19
Primary: Testing Uptake- The Number of Valid Responses That Confirmed COVID-19 Testing Was Completed by Households — .1603; .2552; .2484 Valid response to message on testing
Early Phase 1 N=26 Sex Differences in the Dilatory Response of Compound 21
Sex Differences
Primary: Microvascular AT2R Sensitivity Following Local Control Treatment — 15; 25 percentage of maximal blood flow